{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:32:03Z","timestamp":1792459923892,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:p>\n                    There is a lack of reliable serum markers to reflect the fibrosis stage and necroinflammation grade in autoimmune hepatitis (AIH) patients. In this study, we investigated the diagnostic potential of a noninvasive serum marker, Golgi protein 73 (GP73), for fibrosis and inflammation in AIH patients. Serum GP73 concentrations were measured in a retrospective cohort of 79 patients with AIH who underwent liver biopsy. The receiver operating characteristic curve was constructed to compare the diagnostic value of GP73, liver stiffness and other 2 serum diagnostic models, namely the aspartate aminotransferase to platelet ratio index and fibrosis-4, for significant liver fibrosis and advanced fibrosis. It also compared the predictive value of GP73 with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) for moderate and severe liver necroinflammation. The results showed that serum GP73 level gradually increased with the stage of liver fibrosis or inflammation. The area under the curve (AUC) of GP73 for the diagnosis of significant and severe hepatic fibrosis was 0.684 (95% confidence interval [CI], 0.547\u20130.820;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.027) and 0.773 (95% CI, 0.665\u20130.882;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) respectively. Although the diagnostic efficacy of GP73 was lower than that of liver stiffness, the diagnostic efficacy for advanced fibrosis was slightly better than that of the aspartate aminotransferase to platelet ratio index (AUC, 0.698; 95% CI, 0.578\u20130.817;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.003) and fibrosis-4 (AUC, 0.746; 95% CI, 0.632\u20130.860;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). In addition, serum GP73 had high specificity for the diagnosis of moderate and severe necroinflammation, with AUC of 0.841 (95% CI, 0.738\u20130.943;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.011) and 0.783 (95%CI, 0.683\u20130.882;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), which were better than ALT and AST. Multivariate ordinal logistic regression showed that elevated serum GP73 level was an independent risk factor for necroinflammation in AIH patients (odds ratio, 1.021; 95%CI, 0.007\u20130.036;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004). In conclusion, we found that serum GP73 has good diagnostic value for advanced liver fibrosis in AIH and is a potential auxiliary serum diagnostic marker for liver fibrosis. And GP73 can be used as a reliable and simple noninvasive marker for grading hepatic inflammation with high specificity and better diagnostic efficacy than ALT and AST.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000043064","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:01:52Z","timestamp":1751295712000},"page":"e43064","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic value of serum Golgi protein 73 in liver fibrosis and inflammation in patients with autoimmune hepatitis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6357-7937","authenticated-orcid":false,"given":"Yazhen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-5006","authenticated-orcid":false,"given":"Aifang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6149-3850","authenticated-orcid":false,"given":"Jiahui","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260813","doi-asserted-by":"crossref","first-page":"e070201","DOI":"10.1136\/bmj-2022-070201","article-title":"Diagnosis and management of autoimmune hepatitis.","volume":"380","author":"Muratori","year":"2023","journal-title":"BMJ"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","article-title":"Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.","volume":"110","author":"Roberts","year":"1996","journal-title":"Gastroenterology"},{"key":"R3-20260813","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection.","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.3350\/cmh.2024.0586","article-title":"Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: a systematic review and meta-analysis.","volume":"30","author":"An","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"R5-20260813","doi-asserted-by":"crossref","first-page":"100220","DOI":"10.1016\/j.jtauto.2023.100220","article-title":"Liver inflammation activity in patients with autoimmune hepatitis with normal alanine aminotransferase and immunoglobulin G levels.","volume":"8","author":"Chen","year":"2024","journal-title":"J Transl Autoimmun"},{"key":"R6-20260813","doi-asserted-by":"crossref","first-page":"100321","DOI":"10.1016\/j.jhepr.2021.100321","article-title":"Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis.","volume":"3","author":"Laschtowitz","year":"2021","journal-title":"JHEP Rep"},{"key":"R7-20260813","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12876-023-02685-8","article-title":"Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis.","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"R8-20260813","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-12-17","article-title":"Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis.","volume":"12","author":"Zhou","year":"2012","journal-title":"BMC cancer"},{"key":"R9-20260813","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1515\/CCLM.2011.640","article-title":"Golgi protein 73(GP73), a useful serum marker in liver diseases.","volume":"49","author":"Liu","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"R10-20260813","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3748\/wjg.v26.i34.5130","article-title":"Golgi protein-73: a biomarker for assessing cirrhosis and prognosis of liver disease patients.","volume":"26","author":"Gatselis","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R11-20260813","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cca.2019.02.019","article-title":"Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B.","volume":"493","author":"Yao","year":"2019","journal-title":"Clin Chim Acta"},{"key":"R12-20260813","first-page":"1309","article-title":"Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis.","volume":"35","author":"Liu","year":"2020","journal-title":"Histol Histopathol"},{"key":"R13-20260813","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2020.07.032","article-title":"Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing.","volume":"74","author":"Galaski","year":"2021","journal-title":"J Hepatol"},{"key":"R14-20260813","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression.","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R15-20260813","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis.","volume":"127","author":"Koyama","year":"2017","journal-title":"J Clin Invest"},{"key":"R16-20260813","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","article-title":"The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis.","volume":"50","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"R17-20260813","first-page":"1075","article-title":"Liver fibrosis: a dynamic and potentially reversible process.","volume":"25","author":"Povero","year":"2010","journal-title":"Histol Histopathol"},{"key":"R18-20260813","doi-asserted-by":"crossref","first-page":"9671","DOI":"10.3390\/ijms24119671","article-title":"Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities.","volume":"24","author":"Pei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R19-20260813","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12016-017-8655-y","article-title":"The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review.","volume":"54","author":"Yao","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"R20-20260813","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/apt.16067","article-title":"Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.","volume":"52","author":"Sonneveld","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20260813","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4103\/MJBL.MJBL_666_23","article-title":"Serum elabela level as a reliable biomarker for predicting of liver fibrosis in Iraqi patients with chronic hepatitis C.","volume":"21","author":"Ali","year":"2024","journal-title":"Med J Babylon"},{"key":"R22-20260813","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-1119(00)00136-0","article-title":"GP73, a novel Golgi-localized protein upregulated by viral infection.","volume":"249","author":"Kladney","year":"2000","journal-title":"Gene"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"e12538","DOI":"10.1111\/cpr.12538","article-title":"Golgi protein 73 and its diagnostic value in liver diseases.","volume":"52","author":"Xia","year":"2019","journal-title":"Cell Prolif"},{"key":"R24-20260813","doi-asserted-by":"crossref","first-page":"11287","DOI":"10.3748\/wjg.v20.i32.11287","article-title":"Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer.","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R25-20260813","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2005.05.028","article-title":"GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma.","volume":"43","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"key":"R26-20260813","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41389-021-00358-3","article-title":"GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells.","volume":"10","author":"Liu","year":"2021","journal-title":"Oncogenesis"},{"key":"R27-20260813","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/apt.17748","article-title":"Systematic review: glycomics as diagnostic markers for hepatocellular carcinoma.","volume":"59","author":"Butaye","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20260813","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/gut.2010.214916","article-title":"Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma.","volume":"59","author":"Mao","year":"2010","journal-title":"Gut"},{"key":"R29-20260813","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.aohep.2022.100720","article-title":"Possible roles of Golgi protein-73 in liver diseases.","volume":"27","author":"Liu","year":"2022","journal-title":"Ann Hepatol"},{"key":"R30-20260813","doi-asserted-by":"crossref","first-page":"3862024","DOI":"10.1155\/2019\/3862024","article-title":"Exploring the diagnostic potential of serum golgi protein 73 for hepatic necroinflammation and fibrosis in Chronic HCV infection with different stages of liver injuries.","volume":"2019","author":"Qian","year":"2019","journal-title":"Dis Markers"},{"key":"R31-20260813","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1572-0241.2004.30572.x","article-title":"Disease- and cell-specific expression of GP73 in human liver disease.","volume":"99","author":"Iftikhar","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R32-20260813","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3233\/CBM-2012-00276","article-title":"Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.","volume":"11","author":"Liang","year":"2012","journal-title":"Cancer Biomark"},{"key":"R33-20260813","doi-asserted-by":"crossref","first-page":"4253566","DOI":"10.1155\/2022\/4253566","article-title":"Diagnostic value of serum golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis.","volume":"2022","author":"Yao","year":"2022","journal-title":"Dis Markers"},{"key":"R34-20260813","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1053\/jhep.2002.32525","article-title":"Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease.","volume":"35","author":"Kladney","year":"2002","journal-title":"Hepatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:04:16Z","timestamp":1786633456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":34,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043064","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}